STOCK TITAN
  1. Home
  2. News
  3. SXTPW

60 Degrees Pharmaceuticals, Inc. Warrant - SXTPW STOCK NEWS

Welcome to our dedicated page for 60 Degrees Pharmaceuticals Warrant news (Ticker: SXTPW), a resource for investors and traders seeking the latest updates and insights on 60 Degrees Pharmaceuticals Warrant stock.

60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.

Recent achievements include their Chief Executive Officer, Geoff Dow, PhD, planning a clinical trial to study the use of tafenoquine in treating human babesiosis, a tick-borne disease. The Company has been focused on developing new medicines for rare infectious diseases and collaborating with renowned research organizations in the U.S., Australia, and Singapore.

Financially, 60 Degrees Pharmaceuticals recently reported results for the first fiscal quarter of 2024, showcasing a strong commitment to advancing treatments for infectious diseases.

News

60 Degrees Pharmaceuticals Suspends Phase IIB Study of Tafenoquine for COVID-19, Pivots to Refocus on Commercialization of Treatments for Malaria and Tick-Borne Diseases

Rhea-AI Summary
60 Degrees Pharmaceuticals focuses on commercialization of ARAKODA® and plans Phase IIA study of tafenoquine for babesiosis
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.73%
Tags
clinical trial covid-19
-
News

60 Degrees Pharma Withdraws COVID Phase IIB IND, Will Resubmit Pending Assessment of Ability to Meet FDA Requirements

Rhea-AI Summary
60P Australia withdraws IND for ACLR8-LR study of tafenoquine in treating COVID-19; plans to resubmit later in 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-25.48%
Tags
clinical trial covid-19
-
News

60 Degrees Pharmaceuticals to Participate in H.C. Wainwright 25th Annual Global Investment Conference

Rhea-AI Summary
60 Degrees Pharmaceuticals Inc. to participate in H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.85%
Tags
conferences
News

60 Degrees Pharmaceuticals Study Results Published by New Microbes and New Infections Demonstrate Tafenoquine Exhibits Broad Spectrum Antifungal Activity

Rhea-AI Summary
60 Degrees Pharmaceuticals announces non-clinical study results showing tafenoquine exhibits broad spectrum antifungal activity against Candida spp.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.04%
Tags
none
-
News

60 Degrees Pharmaceuticals Receives Additional U.S. Patent Covering Tafenoquine for Prevention of Plasmodium Falciparum Malaria

Rhea-AI Summary
60P awarded additional U.S. patent for tafenoquine, ensuring long-term competitive position for ARAKODA in the U.S. market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.92%
Tags
none
-
News

60 Degrees Pharmaceuticals Registers ACLR8-LR, a Phase IIB Study of Tafenoquine for Treatment of COVID-19, on ClinicalTrials.gov

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.23%
Tags
clinical trial covid-19
News

60 Degrees Pharmaceuticals Awarded Canadian Patent Covering Tafenoquine for Prevention of Malaria in Malaria-Naive Subjects

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.16%
Tags
none
-
News

WallachBeth Capital Announce Closing Of 60 Degrees Pharmaceuticals IPO At $5.30 Per Unit

Rhea-AI Summary
60 Degrees Pharmaceuticals, Inc. has completed its IPO, raising approximately $7.5 million in gross proceeds. The company offered 1,415,095 units at a price of $5.30 per unit. The shares and tradeable warrants are now trading on the Nasdaq Capital Market under the symbols 'SXTP' and 'SXTPW', respectively.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.67%
Tags
none
-
News

60 Degrees Pharmaceuticals Announces Closing of Initial Public Offering

Rhea-AI Summary
60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) has closed its initial public offering, raising approximately $7.5 million in gross proceeds. The offering consisted of 1,415,095 units priced at $5.30 per unit. Each unit includes one share of common stock, one tradeable warrant, and one non-tradeable warrant. The shares and tradeable warrants began trading on the Nasdaq Capital Market under the symbols 'SXTP' and 'SXTPW' respectively. The underwriters have an option to purchase additional shares and warrants up to 15% of the number of units sold.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.67%
Tags
IPO offering
News

WallachBeth Capital Announce Pricing Of 60 Degrees Pharmaceuticals IPO At $5.30 Per Unit

Rhea-AI Summary
WallachBeth Capital LLC announced that 60 Degrees Pharmaceuticals, Inc. priced its IPO of 1,415,095 units at $5.30 per unit, resulting in approximately $7.5 million of gross proceeds. Each unit consists of one share of common stock, one tradeable warrant, and one non-tradeable warrant. The shares and tradeable warrants will trade on the Nasdaq Capital Market under the symbols 'SXTP' and 'SXTPW' respectively.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none

FAQ

What is the current stock price of 60 Degrees Pharmaceuticals Warrant (SXTPW)?

The current stock price of 60 Degrees Pharmaceuticals Warrant (SXTPW) is $0.0156 as of November 4, 2024.

What is 60 Degrees Pharmaceuticals focused on?

60 Degrees Pharmaceuticals is focused on developing new medicines for the prevention and treatment of infectious diseases.

What recent achievement did 60 Degrees Pharmaceuticals announce?

60 Degrees Pharmaceuticals announced a clinical trial to study the use of tafenoquine in treating human babesiosis.

Who is leading the efforts at 60 Degrees Pharmaceuticals?

Geoff Dow, PhD, is the Chief Executive Officer of 60 Degrees Pharmaceuticals.

Stock SXTPW logo
60 Degrees Pharmaceuticals, Inc. Warrant

Nasdaq:SXTPW

SXTPW Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

SXTPW Stock Data

12.21M
Medicinal and Botanical Manufacturing
Pharmaceutical Preparations
United States of America
WASHINGTON